
Amber N Mcelroy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4391823/publications.pdf Version: 2024-02-01



AMRED N MCELDON

#	Article	IF	CITATIONS
1	TALEN-based Gene Correction for Epidermolysis Bullosa. Molecular Therapy, 2013, 21, 1151-1159.	8.2	232
2	Evaluation of TCR Gene Editing Achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases. Molecular Therapy, 2016, 24, 570-581.	8.2	168
3	Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors. Nature Communications, 2019, 10, 5222.	12.8	135
4	Fanconi Anemia Gene Editing by the CRISPR/Cas9 System. Human Gene Therapy, 2015, 26, 114-126.	2.7	94
5	CRISPR/Cas9-based genetic correction for recessive dystrophic epidermolysis bullosa. Npj Regenerative Medicine, 2016, 1, .	5.2	74
6	Base Editor Correction of COL7A1 in RecessiveÂDystrophic Epidermolysis Bullosa Patient-Derived Fibroblasts and iPSCs. Journal of Investigative Dermatology, 2020, 140, 338-347.e5.	0.7	69
7	Keratinocytes from Induced Pluripotent Stem Cells in Junctional Epidermolysis Bullosa. Journal of Investigative Dermatology, 2013, 133, 562-565.	0.7	33
8	CRISPR/Cas9 Targeted Gene Editing and Cellular Engineering in Fanconi Anemia. Stem Cells and Development, 2016, 25, 1591-1603.	2.1	24
9	CRISPR/Cas9-Mediated Correction of the FANCD1 Gene in Primary Patient Cells. International Journal of Molecular Sciences, 2017, 18, 1269.	4.1	23
10	Disruption of HIV-1 co-receptors CCR5 and CXCR4 in primary human TÂcells and hematopoietic stem and progenitor cells using base editing. Molecular Therapy, 2022, 30, 130-144.	8.2	23
11	CRISPR/Cas9-Based Cellular Engineering for Targeted Gene Overexpression. International Journal of Molecular Sciences, 2018, 19, 946.	4.1	19